• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vectura wins IND for drug-device combo for pediatric asthma

January 25, 2017 By Sarah Faulkner

VecturaVectura wins IND for drug-device combo for pediatric asthma said yesterday that the FDA approved an Investigational New Device application for its drug-device combination to treat asthma in children 12 months to 8 years old. The UK-based company’s device, VR647, uses the Akita Jet nebulizer for the delivery of nebulized budesonide.

Vectura’s drug-device combination product provides faster delivery time and better lung deposition of budesonide, according to the company, and enables a patient to potentially lower their dosage while maintaining efficacy.

“VR647 offers substantial potential harnessing of Vectura’s innovative smart nebulizer technology for superior delivery of an existing drug with a proven track record in an established and significant US market,” Vectura Group CEO James Ward-Lilleys said in prepared remarks. “The FDA’s approval is an important milestone allowing us to commence an accelerated clinical program ahead of potential launch in 2021 as a self-commercialized asset.”

In June 2015, the FDA approved the company’s plan to follow the 505(b)(2) pathway, with the ultimate goal of filing a New Drug Application. The pathway requires that Vectura conduct a small number of clinical studies, which it can begin doing since the FDA approved its IND.

The company plans to initiate its phase I pharmacokinetic study in adults in the 1st half of 2017. The study aims to establish safe dose levels for a phase II study in children, which the company expects will commence in the 2nd half of 2018. Finally, Vectura said it expects to launch a phase III trial in the 2nd half of 2018 and to file the NDA in 2020.

In November last year, Vectura executive James Ward-Lilley was reportedly looking to buy a specialized lung drug business.

Reuters reported that Ward-Lilley was on the hunt for a company with an established U.S. sales force to grow the company’s portfolio and goals as it develops specialized lung drugs that are wholly owned by Vectura.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory Tagged With: Vectura

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS